Prognostic factors in patients with recently diagnosed incurable cancer: a systematic review

被引:103
作者
Hauser, Catherine A.
Stockler, Martin R.
Tattersall, Martin H. N.
机构
[1] Univ Sydney, Dept Canc Med, Sydney, NSW 2006, Australia
[2] Royal Prince Alfred Hosp, Sydney Canc Ctr, Camperdown, NSW 2050, Australia
[3] NH&MRC Clin Trials Ctr, Camperdown, NSW 1450, Australia
关键词
prognosis; prognostic factor; advanced cancer;
D O I
10.1007/s00520-006-0079-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Goals of work: To review the literature and develop a conceptual framework about prognostic factors for people presenting to medical oncologists with recently diagnosed incurable cancer. Materials and methods: Medline was searched from January 2000 to October 2003 to identify articles testing associations between clinical or laboratory variables and survival time in adults with advanced solid tumours and median survival of 3 to 24 months. We recorded how frequently prognostic factors were significantly associated with survival in univariable and multivariable analyses. Results: There were 53 studies included. The factors associated with survival were organised into four categories related to attributes of the host the tumour, the treatment and the interactions between host, tumour and treatment (symptoms, quality of life, performance status and laboratory tests). Co-morbidity was consistently associated with shorter survival. Age and gender were not consistently associated with survival duration, except in lung cancer where females survived longer. Tumour-related factors associated with shorter survival included primary tumour (lung), metastatic site (liver, brain and visceral) and disease extent. Symptoms associated with shorter survival included those of the anorexia-cachexia syndrome, dyspnoea, pain and impaired physical well being. Performance status was strongly associated with survival in most studies. Laboratory tests associated with shorter survival included anaemia, thrombocytopenia, hypoalbuminaemia and elevated serum levels of both alkaline phosphatase and lactate dehydrogenase. Conclusion: Prognostic factors in patients with advanced cancer can be conceptualised as attributes of the host, tumour, treatment and interactions between the three reflected in symptoms, quality of life performance status and laboratory tests.
引用
收藏
页码:999 / 1011
页数:13
相关论文
共 69 条
[21]   Independent prospective validation of the PaP score in terminally ill patients referred to a hospital-based palliative medicine consultation service [J].
Glare, P ;
Virik, K .
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT, 2001, 22 (05) :891-898
[22]   Hormone-resistant prostate cancer with symptomatic pelvic tumours:: patient survival and prognostic factors [J].
Hernes, EH ;
Linja, M ;
Fosså, SD ;
Visakorpi, T ;
Berner, A ;
Winderen, M ;
Koivisto, PA .
BJU INTERNATIONAL, 2000, 86 (03) :240-247
[23]  
Ikeda W, 2001, CANCER-AM CANCER SOC, V91, P490, DOI 10.1002/1097-0142(20010201)91:3<490::AID-CNCR1027>3.0.CO
[24]  
2-L
[25]   Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments:: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-α2a (IFNα) and interleukin 2 (IL-2) with or without cisplatin [J].
Keilholz, U ;
Martus, P ;
Punt, CJA ;
Kruit, W ;
Mooser, G ;
Schadendorf, D ;
Liénard, D ;
Dummer, R ;
Koller, J ;
Voit, C ;
Eggermont, AMM .
EUROPEAN JOURNAL OF CANCER, 2002, 38 (11) :1501-1511
[26]   A phase III randomized trial comparing vindesine and cisplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer: long-term follow-up results and analysis of prognostic factors [J].
Kodani, T ;
Ueoka, H ;
Kiura, K ;
Tabata, M ;
Takigawa, N ;
Segawa, Y ;
Moritaka, T ;
Hiraki, S ;
Harada, M ;
Tanimoto, M .
LUNG CANCER, 2002, 36 (03) :313-319
[27]   Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer:: results of a multivariate analysis of 3825 patients [J].
Köhne, CH ;
Cunningham, D ;
Di Costanzo, F ;
Glimelius, B ;
Blijham, G ;
Aranda, E ;
Scheithauer, W ;
Rougier, P ;
Palmer, M ;
Wils, J ;
Baron, B ;
Pignatti, F ;
Schöffski, P ;
Micheel, S ;
Hecker, H .
ANNALS OF ONCOLOGY, 2002, 13 (02) :308-317
[28]   Identification and interpretation of clinical and quality of life prognostic factors for survival and response to treatment in first-line chemotherapy in advanced breast cancer [J].
Kramer, JA ;
Curran, D ;
Piccart, M ;
de Haes, JCJM ;
Bruning, P ;
Klijn, J ;
Van Hoorebeeck, I ;
Paridaens, R .
EUROPEAN JOURNAL OF CANCER, 2000, 36 (12) :1498-1506
[29]   Long term analysis of survival in the European randomized trial comparing vinorelbine/cisplatin to vindesine/cisplatin and vinorelbine alone in advanced non-small cell lung cancer [J].
Le Chevalier, T ;
Brisgand, D ;
Soria, JC ;
Douillard, JY ;
Pujol, JL ;
Ruffie, P ;
Aberola, V ;
Cigolari, S .
ONCOLOGIST, 2001, 6 :8-11
[30]   Factors of importance for prediction of survival in patients with metastatic renal cell carcinoma, treated with or without nephrectomy [J].
Ljungberg, B ;
Landberg, G ;
Alamdari, FI .
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY, 2000, 34 (04) :246-251